Mon, Nov 24, 2014, 7:52 AM EST - U.S. Markets open in 1 hr 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

  • venture009 venture009 Dec 28, 2009 5:18 PM Flag

    The Share Price

    12 months ago the share was approximately $1.80 cdn. During this 12 month period a number of key objectives have been met and with these accomplishments I believe we all expected a substantial increase in the value of the shares, which has not happened. The market place clearly doesn't think this stock is worth much,and there is much left to convince the investment community, especially with Rodman's recent downgrade. Why? The most recent financing, although I didn't agree with the timing, puts the company into a strong financial position but none of this seems to be getting the attention of the market. There are a number of trial results anticipated over the next few months but can they be any better than what has been released thus far. It appears more and more ONCY can't secure a partner at a price acceptable to management expectations, which appears to leave only one option, go it alone. Can they do it and what will this cost the shareholders? Do we have more years of toiling with an under performing stock?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Small talk alex, that is one thing consistent about that fraudster and criminal is all he can do is small talk.

      never has small talk alex ever posted anything of value, what a pathetic waste of human sperm he is.

    • "I wouldn't be surprised to see us hit that warrant expiration price by February but of course that's just speculation."

      Eveything is a speculation. Getting up in the morning is a speculation if you believe AMA stats. Getting married is a speculation. Eating at your favorite restaurant is a speculation. So don't stop now. Just ask D2, he is afraid to open an eye in the morning, people drop dead just realizing they woke up alive. I like your speculation tho.

    • "I think Onco can say goodby to the 12 million worth of warrants expiring in February. "

      Current price 2.71,
      current bid 100 shares @ 2.73, current ask 2100 shares at 2.76.

      Watching the tape on Fidelity - to my inexperienced eye it looks like the price is being worked upward. I wouldn't be surprised to see us hit that warrant expiration price by February but of course that's just speculation.

    • Yo king hasbeen

      Your reading comp is problematic, ONC/Y is not sitting on material information regarding new SPA's. I said that I felt there was sufficient results from the both Sarcoma PII and Pallvative Reo/Rad PII to allow ONC/Y to apply for a SPA in either. The results are public. Hence, they are sitting the potential not hidden information. The post in question further speculated the reason for no action on the two indications above was that they are awaiting public results on something else, like the PII for pre-screen EGRF in NSCLC.

      bridge

    • peashitter posted this fraud claptrap;

      <<I agree, I am sure the company is doing everything it can to save up and release the press releases after jan 1st. No need to release in 2009 when there is plenty of year end tax selling going on. >>

      are you suggesting that the company is engaging in fraudulent behaviour??? as far as i know materinal information can't be witheld and must be released without delay. so what kinda shite are you suggesting???

    • Interesting observation. Again the timing of this last financing has to be called into question. It seems management underestimated the market reaction and then possibly the granting of additional options may have also contributed to the most recent weakness.

    • ONC can hold any information as long as they want, if it doesn't impede business or effects the shareholders in adverse way...as long as it is not released to any other parties.
      And you are fooling yourself if you think that nobody( insiders) benefits from news about to be released. At any company. Unless they are bunch of chimps err chumps.

    • Pardon my ignorance but if ONCY has some material information, how long do they have to release it? can they hold on to it untill all their buddies load up before releasing it to the street? Is it legit to keep it under wraps till "next year"?

    • I agree, I am sure the company is doing everything it can to save up and release the press releases after jan 1st. No need to release in 2009 when there is plenty of year end tax selling going on.

    • venture,

      assuming you are not part of the criminal element in cowpattytown that has been such a fraudulent gang regarding ONC i will provide you the insite you desire. i accep the share price as being indicative of what the market values ONC (its assets, liabilities, prospects, etc) and "oddly" the responses to you to date have been from the fraudsters, rubes and pumpers, but now for some truth:

      a) ONC has increased its share base by approx 50% in about the last year, and much of that huge dilution has been for very cheap share prices and very "odd" arrangements; lots of cheap shares likely traded out after the last "surprise" financing (although truth be known i did call it fabulously well)

      b) ONC is led by BT (the incompetent), that is almost by itself nuff said, but he is simply the most incompetent CEO i've ever seen for a biotech; he has no record of success in any biotech venture he has ever been involved in; he is a serial and nonstop loser in this regard (i always challenge the fraudsters to post any success he's had (and by success i don't mean managing to keep his job but i mean leading any therapy to market)

      c) strategic error and failure after srategic error and failure on the therapy front; it now appears that ONC's abandoning local admin was another huge strategic error (que up biovex); i also suggest going for non-front line status in H&N is very suboptimal to going for front line status (and of course if biovex gains front line status what will happen to reolysin's potential market, i suggest it will decrease and potentially substantially)

      d) highly questionable transactions and transactions that kill shareholder wealth creation; that very "odd" deal with some failed dickass biotech in Edmonton (Valens or something like that) is a perfect example; IMO warrants based financings are "weak firm" financings that will by default almost always pressure share price over and above normal diluation (and ONC has used this candy as its base financing strategy)

      e) a very weak BoD's; who on that BoD's has any significant successful biotech expertise; what do all those directors from cowpattytown and alberta bring to ONC??? IMO nothing that can't be replaced and upgraded

      f) partnership crappola shite spewing by BT (the incompetent); he has been spewing about potential partnership for years and years and years and has failed miserably to deliver a partnership

      g) failed, deficient and pathetic communications; BT (the incompetent) spews a non-stop drool of WABS (que up the most recent crappola re. this PIII trial) that IMO destroys shareholder confidence

      h) highly questionable business actions; why buy a piece of some crappola BC biotech??? why start up a subsidiary in some island in the caribeann with directors that are not id'ed to shareholders (will this create or destroy potential shareholder wealth)??

      so in sum IMO ONC largely due to BT (the incompetent) and the incompetent BoD's is an exceptionally high risk investment (and less from the reolysin/clinical side and much more from the incompetent leadershi, execution and decision making side) is valued where it is valued.

      so why do i stay an owner of ONC, entirely because i believe Reolysin will some day before the end of time make it to the market.

      and PS i have learned from experience to never believe any shite that BT (the incompetent) spews, double all his timelines and you will do much better.

    • View More Messages
 
ONCY
0.6943+0.0343(+5.20%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.